Meeting
2019 ASCO Annual Meeting
Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
Authors
Bassel Nazha
Emory University Hematology Medical Oncology-Fellowship Program, Atlanta, GA
Bassel Nazha , Zhengjia Chen , Subir Goyal , Anne Engelhart , Jennifer Wilkinson Carlisle , Tyler Beardslee , Harpaul Gill , Levani Odikadze , Yuan Liu , Manoj K. Mishra , Madhusmita Behera , Suresh S. Ramalingam , Taofeek Kunle Owonikoko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9042)
DOI
10.1200/JCO.2019.37.15_suppl.9042
Abstract #
9042
Poster Bd #
365
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.
First Author: Ranjan Pathak
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre
Poster
2021 ASCO Annual Meeting
Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.
First Author: Alex K. Bryant
Poster
2019 ASCO Annual Meeting
Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).
First Author: Alessandro Russo